October 1, 2025Open Access

A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Comprehensive multi-omic study reveals Th17 cells' role in immune checkpoint inhibitor response in mRCC, suggesting potential for biomarkers.

Enriched Th17 CD4+ T cells correlate with positive treatment response in metastatic renal cell carcinoma patients undergoing cICI.
Responders showed significant upregulation in IL-21 pathways and IL-17 signaling, indicating effective immune responses.
Multi-omic approaches, including mass cytometry and RNA sequencing, enabled detailed analysis of immune profiles in mRCC patients.
Findings underscore the potential of Th17-targeting strategies to improve immunotherapy outcomes in cancer treatment.

Guglietta et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Comprehensive multi-omic study reveals Th17 cells' role in immune checkpoint inhibitor response in mRCC, suggesting potential for biomarkers.